GW Starts Canadian Medicinal Cannabis Trials

[Max]

GW Starts Canadian Medicinal Cannabis Trials
LONDON (Reuters) - GW Pharmaceuticals Plc, a British company developing the world's first cannabis-based medicines for pain relief, said on Tuesday it was starting clinical trials in Canada.

The Phase II trial -- the only one of its kind in North America -- will take place under the supervision of Dr. Daniel DeForge of the Rehabilitation Centre, Ottawa Hospital. It will include suffers of multiple sclerosis, spinal cord injury and other forms of chronic pain.

GW Pharma, which floated in London in June, already has an advanced trials program in Britain where its cannabis-based medicine entered final Phase III tests on patients in May.

The Salisbury-based firm is developing prescription drugs to harness the medicinal benefits of cannabis and has created a product which will be delivered using an under-the-tongue spray.


Email this story - View most popular | Printer-friendly format